Lucy To - 26 Aug 2025 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Financial Officer
Signature
/s/ Lucy To
Issuer symbol
SABS
Transactions as of
26 Aug 2025
Net transactions value
$0
Form type
4
Filing time
28 Aug 2025, 17:10:04 UTC
Previous filing
13 Aug 2024
Next filing
05 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
To Lucy Chief Financial Officer 777 W 41ST STREET, SUITE 401, MIAMI BEACH /s/ Lucy To 28 Aug 2025 0002032049

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Stock Option (right to buy) Award $0 +1,200,000 $0.000000 1,200,000 26 Aug 2025 Common Stock 1,200,000 $2.17 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").
F2 The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.
F3 The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Remarks:

Chief Financial Officer